Hereditary Cancer in Clinical Practice This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

CD36 – a plausible modifier of disease phenotype in familial adenomatous polyposis
ConclusionsThis study provides evidence for patients belonging to the MCR and AFAP groups harbouring specific genotypes for SNPs inCD36 to initiate screening/treatment for FAP at much earlier (MCR) and much later (AFAP) ages than the norm in today ’s clinical practice. The findings need to be verified in an independent FAP patient cohort. (Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - July 28, 2018 Category: Cancer & Oncology Source Type: research

A qualitative study of barriers to genetic counseling and potential for mobile technology education among women with ovarian cancer
ConclusionsThese data reiterate previously reported barriers to genetic counseling as observed in other populations. Participants were supportive of the use of mobile technology for promoting uptake of genetic counseling. (Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - July 4, 2018 Category: Cancer & Oncology Source Type: research

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
ConclusionA relativelyhigh incidence of pathogenic non-founder BRCA1/2 mutations wasobserved in a founder population. The Manchester scoring system predicted the probability of non-founder pathogenic mutations with high accuracy. (Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - June 5, 2018 Category: Cancer & Oncology Source Type: research

Patient and provider perspectives on adherence to and care coordination of lynch syndrome surveillance recommendations: findings from qualitative interviews
ConclusionThe maximal benefits of screening for confirmation of LS will only be realized with adherence to recommended preventive care. Important factors to ensure patients receive recommended LS care include a comprehensive and coordinated monitoring program that includes reminder prompts, and increased PCP education of LS and associated surveillance recommendations. (Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - May 10, 2018 Category: Cancer & Oncology Source Type: research

Retraction Note to: The BRCA2 variant c.68 –7 T  & gt;  A is associated with breast cancer
This article [1] has been retracted at the request of the authors. Upon re-review of the data, the authors identified coding errors in this study. (Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - May 2, 2018 Category: Cancer & Oncology Source Type: research

Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
ConclusionThe results of the study confirm the high pCR rate in BRCA1-positive breast cancer after platinum-based neoadjuvant chemotherapy. Larger randomized studies and longer follow-up times are necessary to evaluate the role of platinum-based therapies in BRCA1-positive breast cancer. (Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - April 27, 2018 Category: Cancer & Oncology Source Type: research

Challenges in recruiting African-American women for a breast cancer genetics study
ConclusionsRecruiting African-American women into our breast cancer genetics study proved challenging primarily due to difficulty establishing contact with potential participants. Given their prior participation in breast cancer research, we anticipated that this would be a highly motivated population. Indeed, when we were able to contact SFTC participants, only 14.9% declined to participate in our study. Innovative communication, retention, and recruitment strategies are needed in future studies to address the recruitment challenges we faced. (Source: Hereditary Cancer in Clinical Practice)
Source: Hereditary Cancer in Clinical Practice - April 24, 2018 Category: Cancer & Oncology Source Type: research